Experimental Agent Blocks Prostate Cancer In Animal Study
Friday, May 23, 2008 - 09:28
in Health & Medicine
An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows. The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process. The study showed that the agent kept mice with a precancerous condition from developing advanced prostate cancer. Human testing of the compound is expected to begin early next year.
Read the whole article on Science Daily
More from Science Daily
Related
- Experimental agent blocks prostate cancer in animal studyThu, 22 May 2008, 12:07:43 EDT
- Researchers find cancer-inhibiting compound under the seaThu, 7 Aug 2008, 17:28:48 EDT
- Compounds could be new class of cancer drugsTue, 3 Feb 2009, 16:15:41 EST
- USC researchers identify novel approach for suppressing prostate cancer developmentMon, 24 Nov 2008, 18:01:08 EST
- Blocking signaling protein prevents prostate cancer spread, Jefferson scientists findMon, 2 Jun 2008, 9:22:03 EDT